Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Breast ; 20(6): 574-8, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21852136

ABSTRACT

Metastatic breast cancer is mostly incurable. Progressively overall survival (OS) has improved but few authors have studied treatment globally versus for each line and demonstrated the interest of chemotherapy (CT) after the third line. We selected recent patients treated during the "taxane/anti-aromatase era" for each line given. 529 received CT and 383 hormonotherapy. OS was assessed; from the date of first metastasis and from Day 1 of each CT line. Median OS was 34.1 months; 226 patients received >3 lines of CT with a steady median OS for late lines, 11.4 months per line (range 10.4-12.6). Clinical benefit after the third line of CT was obtained for 29.2-36.6% of patients. CT lasted 11.7 months "on"versus 20.6 months "off" CT. These results may support the use of more than 3 CT lines; each line can contribute to a longer survival.


Subject(s)
Breast Neoplasms/therapy , Neoplasm Recurrence, Local/therapy , Practice Patterns, Physicians' , Antineoplastic Combined Chemotherapy Protocols , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Combined Modality Therapy , Decision Making , Female , France , Humans , Mastectomy , Medical Oncology , Neoplasm Metastasis , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Retrospective Studies , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL